SPOTLIGHT -
Dr Tsao on the Role of Nivolumab Plus Cabozantinib in Advanced RCC
Che-Kai Tsao, MD, discusses key updates from the phase 3 CheckMate 9ER trial, and how these data clarify the role of nivolumab plus cabozantinib as a new standard of care in renal cell carcinoma.
Read More
Dr Tsao on the Investigation of Cabozantinib With Nivolumab and Ipilimumab in RCC
Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.
Dr Tsao on First-line Treatment Approaches in Clear Cell RCC
Che-Kai Tsao, MD, discusses first-line treatment approaches for patients with clear cell renal cell carcinoma.
Dr. Tsao on Improving Outcomes in RCC
Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.
Dr. Tsao on Rationale for Staging Renal Cell Carcinoma
Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma
Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer
Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC
Trastuzumab Deruxtecan Elicits Response in Difficult-To-Treat HER2+ Solid Tumors
